☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
glyconex
GlycoNex Reports Licensing Agreement to Develop SPD8 (Biosimilar, Prolia and Xgeva)
January 7, 2025
GlycoNex Reports the Completion of P-I Study Assessing SPD8 (Biosimilar, Prolia) for Osteoporosis
August 16, 2024
GlycoNex and PrecisemAb Join Hands to Develop New Anti-Glycan Antibodies for Cancer Therapy
May 28, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.